Short answer · Medically reviewed summary · Last updated: 2023-07-13
Tetrahydrobiopterin (BH4) deficiency is a rare genetic disorder that affects the production and recycling of a molecule called tetrahydrobiopterin. This molecule is essential for the proper functioning of several enzymes involved in the production of neurotransmitters, such as dopamine, serotonin, and norepinephrine. The prevalence of Tetrahydrobiopterin Deficiency is estimated to be around 1 in 100,000 to 1 in 200,000 individuals worldwide.
What is the prevalence of Tetrahydrobiopterin Deficiency?
Prevalence of Tetrahydrobiopterin Deficiency: how many people are affected worldwide, differences by sex and region, with sources.
Tetrahydrobiopterin (BH4) deficiency is a rare genetic disorder that affects the production and recycling of a molecule called tetrahydrobiopterin. This molecule is essential for the proper functioning of several enzymes involved in the production of neurotransmitters, such as dopamine, serotonin, and norepinephrine.
The prevalence of Tetrahydrobiopterin Deficiency is estimated to be around 1 in 100,000 to 1 in 200,000 individuals worldwide. It is considered a rare disorder, making it relatively uncommon in the general population.
Tetrahydrobiopterin Deficiency can present in different forms, including mild, moderate, and severe. The severe form is the most common and typically appears in infancy or early childhood. Symptoms may include developmental delay, movement disorders, seizures, intellectual disability, and behavioral problems.
Early diagnosis and treatment are crucial for individuals with Tetrahydrobiopterin Deficiency. Treatment often involves supplementation with BH4 and other medications to manage symptoms and improve neurotransmitter production.
It is important to note that the prevalence of Tetrahydrobiopterin Deficiency may vary among different populations and regions. Genetic testing and clinical evaluation are necessary to accurately diagnose and determine the prevalence within specific populations.
